Clinical trials: Inflammatory Bowel Disease 1
Ulcerative Colitis, Telemedicine
The Use of Web-app Constant-Care in Patients With Acute Severe Ulcerative Colitis Treated With Rescue Therapy
The primary aim is to evaluate if introduction of eHealth in its form of the web application Constant-Care (https://ibd.constant-care.com) could reduce the length of hospitalization in patients with acute severe Ulcerative…
- Trial name
- NCT04165265
- Testing
- Constant-Care
- Where
- Denmark
- Volunteers
- 28 people
- Sponsor
- Nordsjaellands Hospital
Radiomics, Multi-omics
Neurophenotype Predicts CD Disease Progression
The goal of this observational study is aimed to develop a novel multimodal neuroimaging-based model to characterize the neurophenotype of Crohn's Disease patients and assess its ability for predicting disease progression, using…
- Trial name
- NCT06452550
- Testing
- Logistic regression (LR) prediction models
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Crohn Disease
Regulatory T-cells and Crohn's Disease
Aim: the main aim of this study is to investigate if immune cells (regulatory T-cells, Th17 cells and other immune cell types) or biomarkers can be used to predict the response or lack of response to treatment with Infliximab.
- Trial name
- CrohnReg (NCT02060318)
- Testing
- Infliximab
- Where
- Denmark
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
Crohn's Disease, Genetic Predisposition
Abnormal Fecal Microbiota in Healthy Subjects at High Risk for Crohn's Disease
Transversal multicentric French study on the microbiota in patients with Crohn's disease and their first degree healthy relatives The primary objective is the comparison of microbiota between patients with CD, healthy controls…
- Trial name
- MAGIC (NCT02826330)
- Testing
- biomarkers
- Where
- 10 sites in France
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Lynch Syndrome, Crohn Disease
A Study for Imaging the Lower Gastrointestinal Tract Using a Retro-TCE Capsule
The investigators have developed an inexpensive tool to take pictures in the lower GI tract without sedation and to look for signs of disease.
- Conditions
- Lynch Syndrome, Crohn Disease, Inflammatory Bowel Diseases, Healthy
- Trial name
- NCT07219537
- Testing
- Feasibility of using an OCT-based Retrograde Tethered Capsule Endomicroscope device to image the lower GI tract
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Crohn's Disease
Relationship Between Prophylactic Drainage and Postoperative Complications (PPOI) in Crohn's Patients After Surgery
For patients with Crohn's diseases，whether prophylactic abdominal drainage is necessary need further exploration. the present study is focusing on the necessity of prophylactic abdominal drainage in CD patients after surgery.
- Trial name
- RBPD (NCT03815851)
- Testing
- prophylactic drainage, no prophylactic drainage
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jinling Hospital, China
Colitis, Ulcerative, Crohn Disease
Unraveling a Potential Connection Between Bilirubin Metabolism, Gut Microbiota and Inflammatory Bowel Diseases
Inflammatory Bowel Diseases (IBDs) are a set of recurrent inflammatory conditions that include the colon and small intestine. The two principal conditions include Crohn's disease (CD) and ulcerative colitis (UC).
- Trial name
- NCT03841045
- Where
- Israel
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Soroka University Medical Center
Crohn's Disease
An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective upadacitinib is in treating moderately to severely active CD in real world.
- Trial name
- NCT06023030
- Where
- 104 sites in Japan
- Volunteers
- 240 people
- Sponsor
- AbbVie
Crohn´s Disease
Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's Disease
This study will run in centers in Germany, Denmark, Austria, Czech Republic, and Switzerland, only. This proof-of-concept study aims to evaluate the efficacy of three doses of oral TSO suspension vs.
- Trial name
- TRUST-2 (NCT01279577)
- Testing
- Low dose TSO, Medium dose TSO, High dose TSO
- Where
- Germany
- Volunteers
- 254 people
- Sponsor
- Dr. Falk Pharma GmbH
Crohn's Disease
Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease
This study will evaluate higher versus standard adalimumab dosing regimens for induction and maintenance therapy in subjects with moderately to severely active Crohn's Disease and evidence of mucosal ulceration.
- Trial name
- NCT02065570
- Testing
- Adalimumab
- Where
- 143 sites in United States, Austria and 18 more
- Volunteers
- 514 people
- Sponsor
- AbbVie
Crohn's Diseases
Effect of Intestinal Carriage of *Pilosibacter Rotomagensis* on Intestinal Inflammatory Activity
Crohn's disease is a chronic inflammatory condition that can affect the entire digestive tract. The terminal ileum is the segment most frequently involved, and approximately one-third of patients present with disease limited to…
- Trial name
- ProsPec (NCT07871383)
- Testing
- Microbiota suspension
- Where
- France
- Volunteers
- 116 people
- Sponsor
- University Hospital, Rouen
Ulcerative Colitis, Crohn's Disease
A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's Disease
This study will evaluate pharmacokinetics, pharmacodynamics and safety of etrolizumab in pediatric patients of 4 to <18 years of age with moderate to severe ulcerative colitis (UC) or with moderate to severe Crohn's disease (CD).
- Trial name
- FENNEL (NCT03478956)
- Testing
- Etrolizumab
- Where
- 5 sites in Belgium, Poland and 2 more
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Crohn Disease
Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease
This randomized, controlled study aims to evaluate the impact of therapeutic intervention (step up) for the patients who are clinical remission with Magnetic Resonance Enterocolonography (MREC) active.
- Trial name
- NCT02332356
- Testing
- azathioprine or adalimumab and infliximab
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Tokyo Medical and Dental University
Crohn Disease
Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464, administered once daily (QD), in inducing clinical remission and endoscopic response in patients with moderate to severe…
- Trial name
- NCT03905109
- Testing
- ABX464
- Where
- Belgium
- Sponsor
- Abivax S.A.
Crohn's Disease
A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active Crohn's disease (CD).
- Trial name
- NCT03105128
- Testing
- risankizumab IV, risankizumab SC
- Where
- 475 sites in United States, Argentina and 42 more
- Volunteers
- 931 people
- Sponsor
- AbbVie
Crohn Disease Haemorrhagic Rectocolitis
Study of the Impact of a Physical Activity Programme on the Quality of Life of Patients With Inflammatory Bowel Disease
Regular physical activity at a mild to moderate intensity can control inflammation in general and intestinal inflammation in particular during IBD.
- Trial name
- APMICI (NCT05099653)
- Testing
- physical activity
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Raincy Montfermeil Hospital Group
Crohn's Disease, Ulcerative Colitis
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
Since their appearance more than a decade ago, anti-tumor necrosis factor (TNF) inhibitors have demonstrated beneficial activity in the treatment of inflammatory bowel diseases (IBD).
- Trial name
- ATAIM (NCT02508012)
- Testing
- Immuno monitoring
- Where
- France
- Volunteers
- 260 people
- Sponsor
- University Hospital, Montpellier
Crohn Disease (CD)
Kinetics of Transmural Healing in Patients With Crohns Disease Treated With Risankizumab (SKYRIZI®)
Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) that can highly alter patients' quality of life and lead to bowel damage due to its transmural pattern.
- Trial name
- SKYNETICS (NCT07308067)
- Where
- 4 sites in France
- Volunteers
- 109 people
- Sponsor
- University Hospital, Clermont-Ferrand
Crohn's Disease
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.
- Trial name
- DUET-CD (NCT05242471)
- Testing
- Guselkumab, Golimumab, JNJ-78934804
- Where
- 456 sites in United States, Australia and 34 more
- Volunteers
- 703 people
- Sponsor
- Janssen Research & Development, LLC
Crohn's Disease
Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation
The purpose of this study is to evaluate the effects and safety of OPS-2071 (150, 300, or 600 mg twice a day [BID]) versus placebo, as add-on therapy in participants with Crohn's disease who show symptoms of active inflammation…
- Trial name
- NCT03850509
- Testing
- OPS-2071
- Where
- 31 sites in United States, Poland
- Volunteers
- 3 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.